European Commission has approved two new indications for ramucirumab.
“Lung and colorectal cancer are the two top leading causes of cancer deaths in the EU and, despite treatment advances, there continues to be a significant need for new second-line treatment options for people with these types of cancer,” said Richard Gaynor, M.D., senior vice president of product development and medical affairs for Lilly Oncology.
“We are pleased to offer ramucirumab as a new option in these treatment settings as we continue delivering on Lilly’s commitment to people living with lung and gastrointestinal cancers.”
(20 Jan 2017)
(19 Jan 2017)